Company: IMNN
Filing Date: 2025-03-19
Form Type: DRS
Source: 0001641172-25-000007
Chunk: 21

Company: Imunon, Inc.
Filing Date: 2025-03-19
Form: DRS
Chunk 21
---
 operating results, capital requirements, general business conditions and other factors that our board of directors may deem relevant. As a result, capital appreciation, if any, of the securities will be the sole source of gain, if any, for the foreseeable future.

| 9 |

| CONFIDENTIAL TREATMENT REQUESTED BY IMUNON, INC.PURSUANT TO 17 C.F.R. SECTION 200.83 |

<div align='center'>CAPITALIZATION</div>

The following table sets forth our consolidated cash and cash equivalents and capitalization as of December 31, 2024:

| ● | on                                                                                                                              
 an actual basis; and                                                                                                            |
| ● | on                                                                                                                              
 an as adjusted basis to give effect to the sale of [●] shares of Common Stock and accompanying common warrants in the offering, 
 after deducting Placement Agents fees and estimated offering expenses payable by us, and assuming no sale of any pre-funded     
 warrants in this offering and no exercise of the common warrants issued in connection with this offering.                       |

You should read the following table in conjunction with the sections entitled “ Use of Proceeds” included elsewhere in this prospectus and “ Management’s Discussion and Analysis of Financial Condition and Results of Operations” and our audited consolidated financial statements and related notes included in our Annual Report on Form 10-K for the year ended December 31, 2024, incorporated herein by reference.

|                                                                                                                                                                             |     | Actual |              |   |     | As Adjusted |
|:----------------------------------------------------------------------------------------------------------------------------------------------------------------------------|:----|:-------|-------------:|:--|:----|:------------|
| Cash and cash equivalents                                                                                                                                                   |     | $      |    5,872,767 |   |     | $           |
| Stockholders’ equity:                                                                                                                                                       |     |        |              |   |     |             |
| Preferred stock, par value $0.01 per share; 100,000 shares authorized; 0 shares issued and outstanding                                                                      |     |        |            — |   |     |             |
| Common stock, par value $0.01 per share; 112,500,000 shares authorized, 14,500,685 shares issued and outstanding, actual, [●] shares issued and outstanding, as adjusted(1) |     |        |      145,007 |   |     |             |
| Additional paid-in capital                                                                                                                                                  |     |        |  410,987,523 |   |     |             |